Plinabulin's Mechanism and Preclinical Evidence - Plinabulin is a unique tubulin binder with a distinct binding site compared to other tubulin-binding agents[16, 21] - Preclinical studies show that Plinabulin, combined with radiation and anti-PD-1, activates dendritic cells (DCs), stimulates T-cell proliferation, and achieves abscopal effects[17, 24] - Plinabulin induces DC maturation, especially when administered after irradiation (IR), and Plinabulin-treated DCs stimulate T cell proliferation, enhanced by combining with IR[25] Clinical Efficacy and Immune Activation - In a Phase 1 study, the Plinabulin triple combination (with radiation and PD-1/PD-L1 inhibitors) led to an 80% disease control rate (DCR) in 10 IO-refractory patients[18, 32] - Durable responses were observed in 2 Hodgkin lymphoma patients who progressed after 12 or 16 prior lines of therapy[33] - Responding patients exhibited early immune activation with DC maturation and proinflammatory monocytes in the peripheral blood across six different cancer types[19, 35] Summary and Future Directions - Plinabulin demonstrates induction of DC maturation and re-sensitization to anti-PD(L)1 in IO-refractory tumors[37] - The impressive overall results, showing a high 80% disease control rate in ICI-refractory and heavily pre-treated patients, warrant further clinical studies of Plinabulin/IO combinations in IO-refractory settings[37, 38]

Company Overview - BeyondSpring Inc. is a clinical-stage global biopharmaceutical company focused on developing cancer therapies, particularly its lead asset Plinabulin, which is in late-stage clinical development for non-small cell lung cancer (NSCLC) and other cancer indications [3] Study Announcement - BeyondSpring announced a poster presentation on the 303 Study, an investigator-initiated study supported by Merck, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled from May 30 to June 3 in Chicago, IL [1] 303 Study Details - The 303 Study is an open-label, single-arm Phase 2 study evaluating the efficacy and safety of Plinabulin in combination with docetaxel and pembrolizumab for previously treated patients with metastatic NSCLC who have progressed after anti-PD-(L)1 inhibitor therapy [4] - The study involves 47 enrolled patients and is conducted at Peking Union Medical College Hospital in Beijing, China, with Dr. Mengzhao Wang as the principal investigator [4] - The primary endpoint is the investigator-based overall response rate (ORR), while secondary endpoints include progression-free survival (PFS), overall survival (OS), duration of response (DoR), and safety [4] Presentation Details - The presentation will take place on May 31, 2025, from 1:30 PM to 4:30 PM CDT at McCormick Place Convention Center, focusing on initial efficacy and safety results related to immune re-sensitization [5]

Core Viewpoint - BeyondSpring Inc. reported its unaudited financial results for Q1 2025, highlighting advancements in its cancer therapeutics, particularly Plinabulin, and the SEED Therapeutics program, while also noting financial performance metrics. Financial Performance - R&D expenses from continuing operations increased by 21% to $874,000 in Q1 2025 from $721,000 in Q1 2024 [5] - G&A expenses from continuing operations rose by 30% to $1,736,000 in Q1 2025 compared to $1,334,000 in Q1 2024 [5] - Net loss from continuing operations was $2,584,000 in Q1 2025, a 24% increase from $2,080,000 in Q1 2024 [5] Clinical Developments - Plinabulin has been administered to over 700 patients, demonstrating a favorable safety profile and potential efficacy in patients who have progressed on PD-1/L1 inhibitors [2] - Early readouts in metastatic non-small cell lung cancer (NSCLC) and Hodgkin lymphoma showed durable responses warranting further evaluation [2] - The RBM39 molecular-glue degrader achieved complete tumor regression in Ewing sarcoma models and is on track for an IND submission mid-2025 [2][7] Corporate Updates - BeyondSpring owns approximately 40% of SEED Therapeutics, which operates independently and has been classified as discontinued operations for financial reporting [4] - The company reported a total asset increase from $34,315,000 as of December 31, 2024, to $37,104,000 as of March 31, 2025 [12][13] - The total liabilities increased from $48,600,000 to $49,771,000 during the same period [13] Shareholder Information - The net loss attributable to BeyondSpring Inc. was $4,477,000 for Q1 2025, compared to a net loss of $3,231,000 in Q1 2024 [15] - Basic and diluted earnings per share improved to $0.11 in Q1 2025 from a loss of $0.08 in Q1 2024 [15]